2026-03-14T14:02:14Z https://miyazaki-u.repo.nii.ac.jp/oai

oai:miyazaki-u.repo.nii.ac.jp:02000875 2025-06-01T23:51:41Z 72 72:30

Resolvin D4 mitigates lipopolysaccharide-induced lung injury in mice Inomata, Rika 60573988 坪内, 拡伸 ツボウチ, ヒロノブ Tsubouchi, Hironobu 坪内 ツボウチ Tsubouchi 拡伸 ヒロノブ Hironobu 宮崎大学 University of Miyazaki Takao, Toshifumi Kurokawa, Mone 60404422 柳, 重久 ヤナギ, シゲヒサ Yanagi, Shigehisa 柳 ヤナギ Yanagi 重久 シゲヒサ Shigehisa 宮崎大学 University of Miyazaki 00839491 酒井, 克也 サカイ, カツヤ Sakai, Katsuya 酒井 サカイ Sakai 克也 カツヤ Katsuya 宮崎大学 University of Miyazaki 宮崎, 泰可 ミヤザキ, タイガ Miyazaki, Taiga 宮崎 ミヤザキ Miyazaki 泰可 タイガ Taiga 宮崎大学 University of Miyazaki open access © 2024 The Authors. Published by Elsevier Ltd. ARDS Inflammation Omega-3 epoxyeicosanoid Oxidative stress Sirtuin-3 Acute respiratory distress syndrome (ARDS) is a life-threatening condition involving severe lung inflammation. The excessive oxidative stress and persistent inflammation that occur in ARDS lead to decreased epithelial integrity and hypoxemia due to pulmonary edema via increased vascular permeability. Resolvin D4 (RvD4) is one of the lipid mediators that is biosynthesized from omega-3 polyunsaturated fatty acids. It plays a role in the resolution of inflammation and reduces oxidative stress and cell death. We investigated the therapeutic potential of the administration of RvD4 in a murine model of lipopolysaccharide (LPS)-induced ARDS. Concurrent with the intratracheal administration of LPS, RvD4 or saline was administered to mice via the caudal vein every 12 h. This treatment with RvD4 alleviated the LPS-induced infiltration of inflammatory cells in lungs, inhibited increased pulmonary vascular permeability, decreased the levels of IL-1β, IL-6, and TNF-α in bronchoalveolar lavage fluid (BALF), and suppressed the reduction of the expression levels of the tight junction protein, Zonula occludens-1 (Zo-1) and the NAD+-dependent deacetylase, Sirtuin-3 (Sirt3). In vitro experiments revealed that in LPS-stimulated BEAS-2B cells, treatment with RvD4 suppressed the increases in the expressions of pro-inflammatory cytokines and maintained the epithelial cell barrier function and cell viability. The silencing of SIRT3 abolished both the anti-inflammatory effect and the retention of cell integrity in BEAS-2B cells. Together these results indicate that treatment with RvD4 can (i) protect against LPS-induced lung injury by inhibiting inflammation, and (ii) maintain epithelial barrier function via a reduction in the downregulation of SIRT3. Elsevier BV eng journal article VoR http://hdl.handle.net/10458/0002000875 https://miyazaki-u.repo.nii.ac.jp/records/2000875 https://doi.org/10.1016/j.plefa.2024.102652 0952-3278 Prostaglandins, Leukotrienes and Essential Fatty Acids 203 102652 102652 https://miyazaki-u.repo.nii.ac.jp/record/2000875/files/1-s2.0-S0952327824000462-main.pdf application/pdf 2.8 MB 2024-12-25